Home / Europe / Germany / Life Sciences & Healthcare

Life Sciences & Healthcare

The CMS Life Sciences und Healthcare Sector Group is made up of over 480 lawyers across Europe, many of whom have specialised in the Life Sciences und Healthcare industry for several years.

The essence of the group's approach is teamwork, working closely as colleagues in Western and Central Europe. The group has complementary expertise in pharmaceutical, biotechnology, medical device, diagnostic and related areas, so can offer pan-European and local, national advice and assistance to the Life Sciences und Healthcare industries.

The group is recognised as having centres of excellence in respect of pharmaceuticals and medical devices in its practices in the United Kingdom, the Netherlands and Germany as well as specialist tax expertise in France.


The CMS Life Sciences und Healthcare Sector Group provides the following comprehensive range of services:

  • Regulatory
  • Pre-clinical and clinical research
  • Collaboration and licensing
  • Financing/M&A stock option schemes
  • Business restructuring
  • Strategic alliances, mergers and acquisitions
  • Distribution and parallel import issues
  • Patent protection and enforcement
  • Branding, trade dress, advertising and labelling
  • Media issues
  • Personal data
  • Product liability and litigation
  • Health and safety
  • EC & competition/competition enforcement
  • Public sector tendering
  • Environment
  • Immigration


For further information on CMS Life Sciences und Healthcare Sector Group please contact Mr. Jens Wagner.

We are strategic partners of

Young Excellence in healthcare

Young Excellence in Healthcare (YEH) is an interdisciplinary network bringing together young professionals from the healthcare sector. It seeks to develop an intelligent framework for delivering health services in the world of tomorrow. CMS Germany advises YEH strategically and exclusively on all legal matters. CMS also acts as a sounding board for the legal issues and healthcare policies YEH wishes to promote.

Law Firm of the Year for Healthcare

JUVE Guide, 2018/2019

Choose area

Lifesciences & Healthcare
Care Mar­ket
As the pop­u­la­tion in Ger­many ages, care and re­tire­ment homes are one of the fast­est-grow­ing sec­tors in the coun­try. As such, they are at­tract­ing in­cre
Lifesciences & Healthcare
The health­care sec­tor in Ger­many is heav­ily reg­u­lated, shaped by a num­ber of very dif­fer­ent in­terests and, above all, sub­ject to con­stant change. Demo
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...


CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...
Can­nabis law and le­gis­la­tion in Ger­many
Med­ic­al use The leg­al­isa­tion of can­nabis for med­ic­al use took place in 2017. It is there­fore per­mit­ted to grow, sell and im­port can­nabis for med­ic­al use in Ger­many.Pur­su­ant to the Ger­man Nar­cot­ics Act...
Con­sulta­tion on the EU’s in­ter­im emis­sions re­duc­tion tar­get for 2040
Un­til 24 June 2023 the European Com­mis­sion is con­sult­ing to gath­er views on the EU’s cli­mate tar­get for 2040.Since the Com­mu­nic­a­tion of the European Green Deal in late 2019, there have been a raft of...
At last: in­valid­ity and re­voc­a­tion ac­tions now avail­able be­fore TM of­fices...
One of the most sig­ni­fic­ant in­nov­a­tions in­tro­duced by the EU Trade Mark Dir­ect­ive 2015/2436 (the so-called trade mark re­form pack­age) was the re­quire­ment for all EU coun­tries to im­ple­ment – where not...
Di­git­al health apps and telemedi­cine in Ger­many
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? Soft­ware as a med­ic­al deviceSoft­ware with­in di­git­al health...
CMS up­dates Ex­pert Guide on can­nabis law and le­gis­la­tion
CMS Ex­pert Guide on can­nabis law and le­gis­la­tion gives stake­hold­ers de­tailed and up­dated in­form­a­tion on the latest de­vel­op­ments in can­nabis reg­u­la­tion in key mar­kets. The Guide now cov­ers two new jur­is­dic­tions:...
European Com­mis­sion amends Art­icle 102 TFEU guid­ance pa­per and an­nounces...
In 2008, the Com­mis­sion ad­op­ted its Guid­ance on the Com­mis­sion`s en­force­ment pri­or­it­ies in ap­ply­ing Art­icle 82 of the EC Treaty (now Art­icle 102 TFEU) to ab­us­ive ex­clu­sion­ary con­duct by dom­in­ant un­der­tak­ings...
Rig­or­ous European le­gis­la­tion bring­ing clar­ity on prop­er green com­mu­nic­a­tion
En­vir­on­ment­al aware­ness and sus­tain­ab­il­ity have been sub­jects of in­tense dis­cus­sions since they are of grow­ing im­port­ance to in­di­vidu­als in their daily de­cisions. Be­cause this di­men­sion of eco­nom­ic com­pet­i­tion...
European Par­lia­ment and Coun­cil ready to start ne­go­ti­ations on EU Data...
In Feb­ru­ary 2022 the European Com­mis­sion presen­ted its pro­pos­al for the EU Data Act, which – if ad­op­ted - will in­tro­duce a far-reach­ing leg­al re­gime on ac­cess to and use of non-per­son­al data in the...
CMS wins with GE Health­care in Fed­er­al So­cial Court
Ham­burg – On Feb­ru­ary 22, 2023, the Fed­er­al So­cial Court ruled that a be­ne­fit as­sess­ment and a price reg­u­la­tion for a medi­cin­al product with a new act­ive in­gredi­ent is un­law­ful for lack of a leg­al basis...
Out with the old, in with the new? Con­sid­er­a­tions for pat­entees in opt­ing...
So far in this series of blog posts, we began with an art­icle that high­lighted some of the key changes between the cur­rent European sys­tem of pat­ent pro­sec­u­tion and en­force­ment and the new Unit­ary Pat­ent...
Mer­ger con­trol re­view be­low fil­ing thresholds – the ECJ Tower­cast judg­ment...
On 16 March 2023, the ECJ de­cided that a M&A trans­ac­tion, which was not sub­ject to ex-ante EU mer­ger con­trol, can be re­viewed – from an ex post per­spect­ive – as to wheth­er the ac­quirer (through the...